Introduction
We have observed that the plasma protein binding of theophylline in normal subjects (Buss et al., 198) and in patients with airways obstruction (Ebden et al., 1984) shows remarkably little variability.
In view of the known influence of renal disease on the protein binding of drugs which bind to albunmin, however (Gugler & Azarnoff, 1976) , we have measured the protein binding of theophylline in plasma from such subjects.
Methods
Twenty-one patients with renal disease and 21 healthy controls matched for age (to within 3 years) and sex were studied. Fourteen patients had chronic renal failure with creatinine clearances below 10 m/min of whom eight were on maintenance haemodialysis and the other seven chronic ambulatory peritoneal dialysis (CAPD). Five patients had the nephrotic syndrome without severe renal excretory impairment (creatinine clearance > 50 ml/min). The uraemic patients were receiving many drugs including multivitamins, aluminium hydroxide and antihypertensives and all the patients with nephrotic syndrome were receiving diuretics. After both patients and subjects gave informed consent (on an interdialysis day in the haemodialysis patients) plasma was obtained and theophylline plasma protein binding measured using the method of Buss et al. (1983) .
Total non-esterified fatty acid concentrations were measured by a modification of the method of Duncombe (1964) . Plasma albumin concentrations were estimated by immuno-nephelometry (Sternberg, 1977) .
three patient groups and plasma albumin concentration was reduced. The plasma non-esterified fatty acid concentrations were similar in all groups and not significantly different from control. When the binding ratio for all patients and controls was related to serum albumin concentration the relationship was significant (r = 0.622, n = 42, P < 0.01) with a slope similar to that obtained by plotting the corresponding values for human serum albumin solution. In the patients with renal excretory impairment, however, the binding was consistently lower than would be found in a similar concentration of human serum albumin ( Figure 1 and Table 1 (Sjoholm et al., 1976) .
CAPD also appears to be associated with hypoalbuminaemia and in fact the plasma albumin and theophylline protein binding were lower in this group than in subjects with nephrotic syndrome, perhaps because marked hypo- Figure 1 The relationship between the % of theophylline free in plasma and the plasma albumin concentration for patients (-chronic renal failure on haemodialysis, chronic renal failure on CAPD, * nephrotic syndrome) and controls (0 related, albeit weakly, to theophylline protein binding (Buss etal., 1983) (Losowsky & Kenwood, 1968) . There are two points of potential clinical significance in this finding. Firstly, it has been reported that theophylline clearance in renal disease is similar to that in normal controls (Krudjan et al., 1982) . This study measured total plasma theophylline clearance, however, so that if protein binding is reduced in renal disease, the plasma clearance of free (and presumably active drug) may be as much as a 50% lower than normal. Similarly the plasma theophylline concentration at any given total plasma drug concentration may be up to 50% greater in patients with renal disease than in controls. Since total plasma concentration is normally used to monitor therapy, such patients may show clinical toxicity at total plasma concentrations normally regarded as within the therapeutic range. Although in most patient with airways obstruction, total plasma drug concentration is a good guide to free theophylline concentration (Ebden et al., 1983) , measurement of free (rather than total) drug concentration may be more valuable in optimising dosage in patients with severe renal disease, should they require theophylline therapy.
